Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|July 22, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-03-2016
- Volume 11
- Issue 8
CordenPharma Expands into Oligonucleotide APIs
Author(s)Pharmaceutical Technology Editors
The company will expand its service offerings to include oligonucleotide API development and manufacture.
Advertisement
On July 1, 2016, CordenPharma announced that the company will expand into the oligonucleotide API development and manufacturing market. Corden has already begun to expand its Boulder, Colorado facility for the manufacture and development of oligonucleotide APIs. The expansion of the Colorado facility is expected to be complete by the end of 2016. This move will broaden the company’s service offerings, which currently include peptides, lipids, and carbohydrates for APIs and drug products.
“Based on the rich pipeline in the growing oligonucleotide field, this is a very logical move for CordenPharma within our current API and drug product manufacturing offerings,” Mimoun Ayoub, director Peptides, Lipids, Carbohydrates and Injectables Platforms, at CordenPharma International, said in a press statement. “The expansion into the oligonucleotide market is a synergistic complement to our outstanding experience in the manufacture of synthetic lipids, peptides, and carbohydrates, which are also used in oligonucleotide drug delivery.”
Source:
Articles in this issue
about 10 years ago
Slower Bio/Pharma Investment Could Hurt CDMOs in 2017about 10 years ago
Supply Chain Partner Scrutiny Moves Beyond GMPsabout 10 years ago
Chiral Advances Demonstrate Promise for API Synthesisabout 10 years ago
NIST Issues mAb Reference Standardabout 10 years ago
EMA Suspends Drugs Due to Flawed Bioequivalence Studiesabout 10 years ago
Shimadzu System Combines HPLC and UHPLC Methodsabout 10 years ago
Catalent to Commercially Supply Palatin FSD Pen Injectorsabout 10 years ago
Zenith Appoints Serialization Directorabout 10 years ago
CSafe Opens Facility in Puerto RicoAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement